What did we learn from the reduction in microvascular end points -- including those reflecting renal function -- reported in the LEADER trial?

What did we learn from the reduction in microvascular end points -- including those reflecting renal function -- reported in the LEADER trial?

What did we learn from the reduction in microvascular end points — including those reflecting renal function — reported in the LEADER trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario